If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
138
results.
Updated on
14/10/2025 [07:12:00]
Results 75 to 100 of 138
Absstract of: US2025281601A1
The invention relates to vaccination of human subjects, in particular elderly, against bacterial infections, wherein the bacterial infection is not pneumococcal, and COVID-19 infections.
Absstract of: JP2024020274A
To provide a drug with antiviral activity against SARS-CoV-2, which can be used for the treatment of a related disease caused by the infection of SARS-CoV-2.SOLUTION: There is provided a substituted aminopropionate compound represented by formula I, a geometric isomer, and a pharmaceutically acceptable salt thereof, a solvate thereof and/or a hydrate thereof, for treating diseases or infections caused by SARS-CoV-2.SELECTED DRAWING: Figure 1
Absstract of: WO2024096742A1
The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of polypeptides.
Absstract of: WO2024096743A1
The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infections, in particular, SARS-CoV-2 infections by means of intranasal administration or oral inhalation of antibodies.
Absstract of: EP4613330A1
An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. The present disclosure further discloses an application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2. Compared to an mRNA vaccine encoding separately corresponding antigens, the mRNA vaccine encoding a fusion antigen provided by the present disclosure can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine only needs to synthesize a single mRNA molecule for the encapsulation within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.
Absstract of: EP4614150A1
The present disclosure provides systems and processes to screen for SARS-CoV-2. This disclosure teaches specific (and different) workable ranges for starting materials in a screening process for different SARS-CoV-2 variants (e.g., the Washington isolate, Alpha variant, Gamma P.1 variant, Beta variant, Iota variant, Delta variant, Omicron BA.1 variants, etc.). As shown herein, each variant has a different combination of starting materials and incubation periods, which further demonstrates the unpredictability of success that is associated with the disclosed systems and the disclosed processes. To be clear, the general ELISA process is well known by those having skill in the art. However, what is neither well known nor intuitive are the specific parameters associated with different process steps within ELISA. Those specific parameters are the subject of this disclosure.
Absstract of: US2025277258A1
This disclosure relates to heteromultivalent nucleic acid-functionalized surfaces, such as particles, and uses in optimizing hybridization specificity for targets containing one, two, or more mutations. In certain embodiments, heteromultivalent hybridization enables fine-tuned specificity for a single SNP and dramatic enhancements in specificity for two non-proximal SNPs empowered by cooperative binding. In certain embodiments, use of specified oligo lengths, spacer lengths, and binding orientation are contemplated. In certain embodiments, this disclosure provides for methods of discrimination between heterozygous cis and trans mutations and between different strains of a virus, e.g., the SARS-CoV-2 virus.
Absstract of: US2025276979A1
The present disclosure relates to compounds of Formula I:and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Absstract of: AU2025217394A1
This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS-CoV- 2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drugs formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations, that are incorporated into a pulmonary and oral delivery systems. This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS-CoV- 2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drugs formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations, that are incorporated into a pulmonary and oral delivery systems. ug h i s i n v e n t i o n r e l a t e s t o t h e u s e o f a n t i - v i r a l d r u g s w i t h d i f f e r e n t m e c h a n i s m s o f a c t i o n u g f o r t h e t r e a t i n g o r p r e v e n t i n g o f v i r a l i n f e c t i o n s s u c h a s - ( a l s o k n o w n a s - o - ) a n d r e d u c i n g m e d i c a l c o m p l i c a t i o n s r e l a t e d t o - v i r a l d i s e a s e h e p r e s
Absstract of: AU2024231716A1
The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 nucleocapsid protein (N-protein) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID- 19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary' Fc fusion proteins and pharmaceutical formulations of exemplary' Fc fusion proteins are provided, in addition to methods of use and preparation.
Absstract of: US2025276955A1
In one aspect, the present disclosure provides compounds which inhibit a coronavirus main protease. In another aspect, the present disclosure provides a method of treating, ameliorating and/or preventing a coronavirus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure. In some embodiments, the method prevents or treats COVID-19 in the subject.
Absstract of: US2025277021A1
The present invention provides methods for preventing and treating cardiac dysfunction, including cardiomyopathy and heart failure. The methods of the invention feature the administration of an antagonist of Activin A, e.g., a therapeutically effective amount of an antibody that binds to and reduces or neutralizes the activity of human Activin A. The methods of the invention are useful in preventing and treating cardiac disease from multiple causes, including viral disease, e.g., COVID-19.
Absstract of: US2025276030A1
Disclosed are methods of treating a subject with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection with EOM613. In several embodiments, a subject at risk of developing severe symptoms of SARS-COV-2 infection is selected for treatment. Also disclosed are methods wherein administering EOM613 reduces symptoms of SARS-COV-2 infection, including symptoms of cytokine storm syndrome or multisystem inflammatory syndrome.
Absstract of: US2025277788A1
A SARS-COV-2 N protein-specific single-chain antibody, a fusion protein, and use thereof are provided. The antibody includes a heavy chain variable region VH, a linker and a light chain variable region VL which are connected in sequence; the amino acid sequence of the heavy chain variable region VH is set forth in SEQ ID NO: 4; and the amino acid sequence of the light chain variable region VL is set forth in SEQ ID NO: 6. Compared with the conventional ELISA detection, the fusion protein can greatly shorten the detection time, can catalyze the substrate to generate a color reaction which can be recognized by naked eyes, and can perform detection without special instruments.
Absstract of: WO2025181504A1
The invention relates to the field of ion exchange based purification processes and provides an improved method for the purification of lipid enveloped viruses. Use of the elution solution significantly enhances the efficiency of the recovery of the infective virus, in particular intact SARS-CoV-2 virions.
Absstract of: US2025276005A1
The invention provides a method for treating SARS-COV-2 by administering an effective amount of pectin polysaccharides to a subject in need thereof.
Absstract of: US2025276056A1
Compositions and methods to induce cytolytic T lymphocytes (CD8+) response, that is, MHC class I restricted T cell responses, to pathogenic and common cold coronaviruses, including a delivery platform for antigens consisting of a polyionic papillomavirus virus-like particle (VLP), with contiguous, negatively charged amino acids flanked by a cysteine residue inserted in the HI loop of the papillomavirus L1 protein. Antigens to be paired with the VLP include fusion peptide/proteins derived from a pathogenic coronavirus, and from the genetically most closely related human coronaviruses that commonly circulate in human populations, with N-terminal or C-terminal amino acids consisting of contiguous, positively charged amino acids preceded and/or followed by a cysteine residue and a C-terminal proteolytic processing sequence (AAYY) to enhance presentation of MHC class I epitopes.
Absstract of: GB2638668A
A method for predicting whether a subject infected with SARS-CoV-2 is likely to be infectious through airborne transmission or not is provided. The method includes determining expression of the TBLIXRI gene and optionally also the MIR4323 gene, the PPP3CB gene and the TRPM2 gene in a biological sample from a subject, typically from a subject who has tested positive for COVID-19. The method can include determining the expression levels of combinations of two or three of these genes, for example TBLIXRI and PPP3CB; TBLIXRI and MIR4323; TBLIXRI and TRPM2; TBLIXRI, PPP3CB and TRPM2; TBLIXRI, MIR4323 and PPP3CB; or TBLIXRI, MIR4323 and TRPM2. The level(s) of expression of the gene(s), through the quantification of mRNA level(s), can be compared to reference levels (non-infectious control subjects) to determine whether the subject is likely to be infectious. The biological sample is typically a blood sample. Also claimed are primer pairs for amplifying the genes.
Absstract of: WO2024089627A1
The invention provides a set of new single domain antibodies - sdAb/Vhh against the nucleoprotein (N) of SARS-CoV-2 and their use for diagnostic, therapeutic and prophylactic applications. Wherein the Vhh is selected from Vhh1 and/ or Vhh2 wherein the Vhh1 comprises 3 CDR having at least a 90% identity with aminoacidic sequence according to SEQ ID No 5, 6 and 7, and Vhh2 comprises 3 CDR having at least a 90% identity with aminoacidic sequence according to SEQ ID No 8, 9 and 10.
Absstract of: WO2024089454A1
The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of post viral infection caused by the virus strain called SARS-CoV-2, or alternatively COVID- 19, chronic fatigue/fatigue.
Absstract of: MX2025000142A
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Absstract of: MX2025008873A
This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS~CoV-2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drags formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations that are incorporated into pulmonary and oral delivery systems.
Absstract of: US12403158B1
A phytochemical and nutraceutical composition and method for protection against a wide spectrum of viral and bacterial infections, including Covid-19, and for treatment of established infection and infectious inflammation. The composition includes a novel combination of vitamin, mineral, nutraceutical and phytochemical supplements. The composition of supplements and method may be compounded as a pill, tablet, powder, capsule or liquid be taken orally one or more times per day, and parenteral including nasal sprays and inhalers. Vitamin C and vitamin E along with zinc complexed with pyrithione or citrate are used in conjunction with nutraceuticals and phytochemicals provided, respectively, as immune boosters and antiviral agents along with anti-inflammatory nutraceuticals and phytochemicals.
Absstract of: WO2025178933A1
Provided herein are antiviral compounds including compounds of Formulae (I), (II'), (II), and (III), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and pharmaceutical compositions thereof. The compounds provided herein are useful for the treatment and/or prevention of infectious diseases (e.g., viral infections including COVID-19). In other aspects, provided herein are kits comprising compounds and pharmaceutical compositions described herein, methods of synthesizing the compounds provided herein, and intermediates useful in the synthesis of compounds provided herein. Formula (II):
Nº publicación: US2025268917A1 28/08/2025
Applicant:
REVEN PHARMACEUTICALS INC [US]
REVEN PHARMACEUTICALS INC
Absstract of: US2025268917A1
The disclosure relates to pharmaceutical compositions and methods for the prevention and/or treatment of inflammation, disease, and disorders. The treatment may include treatment of COVID-19.
BOPI
Electronic site
